70 related articles for article (PubMed ID: 38690288)
21. Dictionary of immune responses to cytokines at single-cell resolution.
Cui A; Huang T; Li S; Ma A; Pérez JL; Sander C; Keskin DB; Wu CJ; Fraenkel E; Hacohen N
Nature; 2024 Jan; 625(7994):377-384. PubMed ID: 38057668
[TBL] [Abstract][Full Text] [Related]
22. Combining BCMA-targeting CAR T cells with TCR-engineered T-cell therapy to prevent immune escape of multiple myeloma.
Wachsmann TLA; Meeuwsen MH; Remst DFG; Buchner K; Wouters AK; Hagedoorn RS; Falkenburg JHF; Heemskerk MHM
Blood Adv; 2023 Oct; 7(20):6178-6183. PubMed ID: 37567150
[No Abstract] [Full Text] [Related]
23. Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering.
Li L; Mohanty V; Dou J; Huang Y; Banerjee PP; Miao Q; Lohr JG; Vijaykumar T; Frede J; Knoechel B; Muniz-Feliciano L; Laskowski TJ; Liang S; Moyes JS; Nandivada V; Basar R; Kaplan M; Daher M; Liu E; Li Y; Acharya S; Lin P; Shanley M; Rafei H; Marin D; Mielke S; Champlin RE; Shpall EJ; Chen K; Rezvani K
Sci Adv; 2023 Jul; 9(30):eadd6997. PubMed ID: 37494448
[TBL] [Abstract][Full Text] [Related]
24. Expression of inducible factors reprograms CAR-T cells for enhanced function and safety.
Smole A; Benton A; Poussin MA; Eiva MA; Mezzanotte C; Camisa B; Greco B; Sharma P; Minutolo NG; Gray F; Bear AS; Baroja ML; Cummins C; Xu C; Sanvito F; Goldgewicht AL; Blanchard T; Rodriguez-Garcia A; Klichinsky M; Bonini C; June CH; Posey AD; Linette GP; Carreno BM; Casucci M; Powell DJ
Cancer Cell; 2022 Dec; 40(12):1470-1487.e7. PubMed ID: 36513049
[TBL] [Abstract][Full Text] [Related]
25. Co-expression IL-15 receptor alpha with IL-15 reduces toxicity via limiting IL-15 systemic exposure during CAR-T immunotherapy.
Zhang Y; Zhuang Q; Wang F; Zhang C; Xu C; Gu A; Zhong WH; Hu Y; Zhong X
J Transl Med; 2022 Sep; 20(1):432. PubMed ID: 36167591
[TBL] [Abstract][Full Text] [Related]
26. Harnessing IL-15 signaling to potentiate NK cell-mediated cancer immunotherapy.
Ma S; Caligiuri MA; Yu J
Trends Immunol; 2022 Oct; 43(10):833-847. PubMed ID: 36058806
[TBL] [Abstract][Full Text] [Related]
27. A novel anti-PD-L1/IL-15 immunocytokine overcomes resistance to PD-L1 blockade and elicits potent antitumor immunity.
Shi W; Lv L; Liu N; Wang H; Wang Y; Zhu W; Liu Z; Zhu J; Lu H
Mol Ther; 2023 Jan; 31(1):66-77. PubMed ID: 36045584
[TBL] [Abstract][Full Text] [Related]
28. T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion.
Morton LT; Wachsmann TLA; Meeuwsen MH; Wouters AK; Remst DFG; van Loenen MM; Falkenburg JHF; Heemskerk MHM
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288464
[TBL] [Abstract][Full Text] [Related]
29. Off-the-Shelf Prostate Stem Cell Antigen-Directed Chimeric Antigen Receptor Natural Killer Cell Therapy to Treat Pancreatic Cancer.
Teng KY; Mansour AG; Zhu Z; Li Z; Tian L; Ma S; Xu B; Lu T; Chen H; Hou D; Zhang J; Priceman SJ; Caligiuri MA; Yu J
Gastroenterology; 2022 Apr; 162(4):1319-1333. PubMed ID: 34999097
[TBL] [Abstract][Full Text] [Related]
30. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
[TBL] [Abstract][Full Text] [Related]
31. piggyBac system to co-express NKG2D CAR and IL-15 to augment the
Du Z; Ng YY; Zha S; Wang S
Mol Ther Methods Clin Dev; 2021 Dec; 23():582-596. PubMed ID: 34853803
[TBL] [Abstract][Full Text] [Related]
32. CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment.
Di Pilato M; Kfuri-Rubens R; Pruessmann JN; Ozga AJ; Messemaker M; Cadilha BL; Sivakumar R; Cianciaruso C; Warner RD; Marangoni F; Carrizosa E; Lesch S; Billingsley J; Perez-Ramos D; Zavala F; Rheinbay E; Luster AD; Gerner MY; Kobold S; Pittet MJ; Mempel TR
Cell; 2021 Aug; 184(17):4512-4530.e22. PubMed ID: 34343496
[TBL] [Abstract][Full Text] [Related]
33. Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells.
Bishop DC; Clancy LE; Simms R; Burgess J; Mathew G; Moezzi L; Street JA; Sutrave G; Atkins E; McGuire HM; Gloss BS; Lee K; Jiang W; Maddock K; McCaughan G; Avdic S; Antonenas V; O'Brien TA; Shaw PJ; Irving DO; Gottlieb DJ; Blyth E; Micklethwaite KP
Blood; 2021 Oct; 138(16):1504-1509. PubMed ID: 34010392
[No Abstract] [Full Text] [Related]
34. Inducible MyD88/CD40 synergizes with IL-15 to enhance antitumor efficacy of CAR-NK cells.
Wang X; Jasinski DL; Medina JL; Spencer DM; Foster AE; Bayle JH
Blood Adv; 2020 May; 4(9):1950-1964. PubMed ID: 32384544
[TBL] [Abstract][Full Text] [Related]
35. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.
Liu E; Marin D; Banerjee P; Macapinlac HA; Thompson P; Basar R; Nassif Kerbauy L; Overman B; Thall P; Kaplan M; Nandivada V; Kaur I; Nunez Cortes A; Cao K; Daher M; Hosing C; Cohen EN; Kebriaei P; Mehta R; Neelapu S; Nieto Y; Wang M; Wierda W; Keating M; Champlin R; Shpall EJ; Rezvani K
N Engl J Med; 2020 Feb; 382(6):545-553. PubMed ID: 32023374
[TBL] [Abstract][Full Text] [Related]
36. Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy.
Shah NN; Qin H; Yates B; Su L; Shalabi H; Raffeld M; Ahlman MA; Stetler-Stevenson M; Yuan C; Guo S; Liu S; Hughes SH; Fry TJ; Wu X
Blood Adv; 2019 Aug; 3(15):2317-2322. PubMed ID: 31387880
[TBL] [Abstract][Full Text] [Related]
37. Engineering antigen-specific NK cell lines against the melanoma-associated antigen tyrosinase via TCR gene transfer.
Parlar A; Sayitoglu EC; Ozkazanc D; Georgoudaki AM; Pamukcu C; Aras M; Josey BJ; Chrobok M; Branecki S; Zahedimaram P; Ikromzoda L; Alici E; Erman B; Duru AD; Sutlu T
Eur J Immunol; 2019 Aug; 49(8):1278-1290. PubMed ID: 31054264
[TBL] [Abstract][Full Text] [Related]
38. NK cells specifically TCR-dressed to kill cancer cells.
Mensali N; Dillard P; Hebeisen M; Lorenz S; Theodossiou T; Myhre MR; Fåne A; Gaudernack G; Kvalheim G; Myklebust JH; Inderberg EM; Wälchli S
EBioMedicine; 2019 Feb; 40():106-117. PubMed ID: 30665853
[TBL] [Abstract][Full Text] [Related]
39. Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia.
van der Lee DI; Reijmers RM; Honders MW; Hagedoorn RS; de Jong RC; Kester MG; van der Steen DM; de Ru AH; Kweekel C; Bijen HM; Jedema I; Veelken H; van Veelen PA; Heemskerk MH; Falkenburg JHF; Griffioen M
J Clin Invest; 2019 Feb; 129(2):774-785. PubMed ID: 30640174
[TBL] [Abstract][Full Text] [Related]
40. IL-15 is a component of the inflammatory milieu in the tumor microenvironment promoting antitumor responses.
Santana Carrero RM; Beceren-Braun F; Rivas SC; Hegde SM; Gangadharan A; Plote D; Pham G; Anthony SM; Schluns KS
Proc Natl Acad Sci U S A; 2019 Jan; 116(2):599-608. PubMed ID: 30587590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
